Literature DB >> 22033402

Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain.

Inken Lorenzen1, Ahmad Trad, Joachim Grötzinger.   

Abstract

A disintegrin and metalloprotease protein 17 (ADAM17) is a transmembrane zinc dependent metalloprotease. The catalytic activity of the enzyme results in the shedding of a broad range of membrane proteins. The release of the corresponding ectodomains induces a switch in various physiological and pathophysiological processes. So far there is not much information about the molecular mechanism of ADAM17 activation available. As for other transmembrane proteases, multimerisation may play a critical role in the activation and function of ADAM17. The present work demonstrates that ADAM17 indeed exists as a multimer in the cell membrane and that this multimerisation is mediated by its EGF-like domain.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033402     DOI: 10.1016/j.bbrc.2011.10.056

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors.

Authors:  Tomohito Gohda; Yasuhiko Tomino
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

Review 2.  Pore-forming bacterial toxins and antimicrobial peptides as modulators of ADAM function.

Authors:  Karina Reiss; Sucharit Bhakdi
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

3.  Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor α ectodomain shedding.

Authors:  Jeanette Schwarz; Stefanie Schmidt; Olga Will; Tomas Koudelka; Kaja Köhler; Melanie Boss; Björn Rabe; Andreas Tholey; Jürgen Scheller; Dirk Schmidt-Arras; Michael Schwake; Stefan Rose-John; Athena Chalaris
Journal:  J Biol Chem       Date:  2013-12-13       Impact factor: 5.157

4.  A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor.

Authors:  Stefan Düsterhöft; Katharina Höbel; Mirja Oldefest; Juliane Lokau; Georg H Waetzig; Athena Chalaris; Christoph Garbers; Jürgen Scheller; Stefan Rose-John; Inken Lorenzen; Joachim Grötzinger
Journal:  J Biol Chem       Date:  2014-04-30       Impact factor: 5.157

Review 5.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

6.  ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.

Authors:  Airi Nishimi; Takeo Isozaki; Shinichiro Nishimi; Sho Ishii; Takahiro Tokunaga; Hidekazu Furuya; Kuninobu Wakabayashi; Tsuyoshi Kasama
Journal:  Clin Rheumatol       Date:  2018-02-06       Impact factor: 2.980

7.  A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers.

Authors:  Hansen J Kosasih; Karena Last; Fraser M Rogerson; Suzanne B Golub; Stephanie J Gauci; Vincenzo C Russo; Heather Stanton; Richard Wilson; Shireen R Lamande; Paul Holden; Amanda J Fosang
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

Review 8.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

9.  A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis.

Authors:  Hong-Bin Liu; Qi-Chang Yang; Yi Shen; Yan Zhu; Xiao-Juan Zhang; Hao Chen
Journal:  Mol Med Rep       Date:  2014-10-29       Impact factor: 2.952

10.  Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma.

Authors:  Xiying Chi; Tao Ji; Junying Li; Jie Xu; Xiaodong Tang; Lu Xie; Fanfei Meng; Wei Guo
Journal:  Cancer Manag Res       Date:  2021-06-28       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.